PG Richardson

1.7k total citations
51 papers, 789 citations indexed

About

PG Richardson is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, PG Richardson has authored 51 papers receiving a total of 789 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 21 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in PG Richardson's work include Multiple Myeloma Research and Treatments (33 papers), Protein Degradation and Inhibitors (13 papers) and Chronic Lymphocytic Leukemia Research (11 papers). PG Richardson is often cited by papers focused on Multiple Myeloma Research and Treatments (33 papers), Protein Degradation and Inhibitors (13 papers) and Chronic Lymphocytic Leukemia Research (11 papers). PG Richardson collaborates with scholars based in United States, United Kingdom and Spain. PG Richardson's co-authors include Francisco J. Plaza Martín, A. J. Patek, Margaret E. Billingham, Edwin L. Alderman, Gerald J. Berry, B L Lum, Frank M. Torti, Richard J. Benjamin, Giovanni Barosi and Richard E. Clark and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

PG Richardson

50 papers receiving 763 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
PG Richardson United States	11	327	260	220	196	137	51	789
Albert C. Yeh United States	17	78 0.2×	217 0.8×	279 1.3×	100 0.5×	32 0.2×	30	905
Eric Davis United States	12	263 0.8×	320 1.2×	207 0.9×	68 0.3×	55 0.4×	29	698
S. Maki Japan	13	95 0.3×	151 0.6×	253 1.1×	130 0.7×	8 0.1×	47	826
Peter Eu Australia	26	27 0.1×	989 3.8×	208 0.9×	92 0.5×	43 0.3×	55	3.1k
Andrew X. Zhu United States	15	55 0.2×	349 1.3×	128 0.6×	68 0.3×	21 0.2×	37	872
Manisha Lamba United States	14	194 0.6×	213 0.8×	159 0.7×	147 0.8×	9 0.1×	44	790
Satoshi Hino Japan	21	43 0.1×	298 1.1×	627 2.9×	85 0.4×	6 0.0×	59	1.3k
Jung Shin Lee South Korea	23	77 0.2×	554 2.1×	590 2.7×	154 0.8×	9 0.1×	86	1.8k
Cristina Solé Spain	21	114 0.3×	43 0.2×	511 2.3×	135 0.7×	5 0.0×	32	1.3k
Martin Wilhelm Germany	15	260 0.8×	842 3.2×	344 1.6×	575 2.9×	9 0.1×	40	1.9k

Countries citing papers authored by PG Richardson

Since Specialization

Citations

This map shows the geographic impact of PG Richardson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PG Richardson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PG Richardson more than expected).

Fields of papers citing papers by PG Richardson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by PG Richardson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PG Richardson. The network helps show where PG Richardson may publish in the future.

Co-authorship network of co-authors of PG Richardson

This figure shows the co-authorship network connecting the top 25 collaborators of PG Richardson. A scholar is included among the top collaborators of PG Richardson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with PG Richardson. PG Richardson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mateos, María‐Victoria, Jelena Bila, Fredrik Schjesvold, et al.. (2023). P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI. HemaSphere. 7(S2). 29–30. 1 indexed citations

Schjesvold, Fredrik, Heinz Ludwig, Sosana Delimpasi, et al.. (2023). P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY. HemaSphere. 7(S2). 32–32. 1 indexed citations

Mateos, María‐Victoria, Sara Bringhen, PG Richardson, et al.. (2014). Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 99(6). 1114–1122. 35 indexed citations

Richardson, PG, Vincent T. Ho, Corey Cutler, et al.. (2012). Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Novel Insights to Pathogenesis, Current Status of Treatment, and Future Directions. Biology of Blood and Marrow Transplantation. 19(1). S88–S90. 29 indexed citations

Morgan, Gillian, Brian G.M. Durie, Jesús F. San Miguel, et al.. (2011). Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM). Haematologica. 96. 4 indexed citations

Miguel, Jesús F. San, Sagar Lonial, Vânia Hungria, et al.. (2011). PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.. Journal of Clinical Oncology. 29(15_suppl). TPS227–TPS227. 9 indexed citations

Jakubowiak, Andrzej, Jack W. Singer, David S. Siegel, et al.. (2010). Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.. Journal of Clinical Oncology. 28(15_suppl). 8003–8003. 5 indexed citations

Flinn, Ian W., J. Wolf, Cristina Gasparetto, et al.. (2009). A247 Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide (VDCR) Has High Efficacy in First-Line MM. Clinical Lymphoma & Myeloma. 9. S43–S44.

Leduc, Renee, Marybeth Nelson, Amy Sam, et al.. (2009). A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S86–S86. 1 indexed citations

10.

Hofmeister, Craig C., Erica Campagnaro, Tara Kendall, et al.. (2009). A268 Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S45–S46. 2 indexed citations

11.

Ruutu, Tapani, Giovanni Barosi, Richard J. Benjamin, et al.. (2007). Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 92(1). 95–100. 266 indexed citations

12.

Mitsiades, Constantine S., Asher Chanan‐Khan, Melissa Alsina, et al.. (2005). Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM). Journal of Clinical Oncology. 23(16_suppl). 3056–3056. 4 indexed citations

13.

Chanan‐Khan, Asher, PG Richardson, Sagar Lonial, et al.. (2005). Safety and Efficacy of Bortezomib in Multiple Myeloma Patients with Renal Failure Requiring Dialysis.. Blood. 106(11). 2550–2550. 10 indexed citations

14.

Chauhan, D, Teru Hideshima, Klaus Podar, et al.. (2002). Heat shock protein-27 confers drug-resistance in multiple myeloma cells.. Blood. 100(11). 2 indexed citations

15.

Chauhan, D, Michael Sattler, Teru Hideshima, et al.. (2001). 2-methoxyestradiol (2ME2) acts directly on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma (MM) cells.. Blood. 98(11). 3 indexed citations

16.

Richardson, PG, RL Schlossman, Teru Hideshima, et al.. (2001). A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM).. Blood. 98(11). 77516. 23 indexed citations

17.

Berry, Gerald J., Margaret E. Billingham, Edwin L. Alderman, et al.. (1998). The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Annals of Oncology. 9(7). 711–716. 203 indexed citations

18.

Richardson, PG, et al.. (1992). Metastatic Melanoma to the Testis Simulating Primary Seminoma. British Journal of Urology. 69(6). 663–665. 7 indexed citations

19.

Richardson, PG, et al.. (1991). The determination of absolute electron affinities of chlorobenzenes, chloronaphthalenes and chlorinated biphenyls from reduction potentials. Journal of Electroanalytical Chemistry. 307(1-2). 169–182. 26 indexed citations

20.

Richardson, PG, et al.. (1987). Phase identification, microstructural characterization, phase microanalyses and leaching performance evaluation of SYNROC-FA crystalline ceramic waste form. Journal of Nuclear Materials. 148(2). 157–165. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact